Human antibodies, pharmaceutical compositions and methods

Abstract

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to Globo H, stage-specific embryonic antigen 3 (SSEA-3) and stage-specific embryonic antigen 4 (SSEA-4)are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cellsurfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 368,407, filed July 29, 2016. The entire content of the above application is incorporated herein by reference. [0003] field of invention [0004] The present disclosure relates to human antibodies and binding fragments thereof that bind carbohydrate antigens, as well as nucleic acids encoding such antibodies, complementary nucleic acids, polypeptides, vectors, host cells, and methods of making and using them, including those comprising said antibodies and / or binding fragments pharmaceutical composition. Additionally, methods of administering an antibody to a subject in an amount effective to inhibit cancer cells are provided. Specifically, disclosed herein are antibodies that bind stage-specific embryonic antigen 3 (SSEA-3), stage-specific embryonic antigen 4 (SSEA-4), and GloboH, as well as related compositions and methods of use. Methods...

AI Technical Summary

Problems solved by technology

Although this technique yields many useful antibodies, its applicability is limited by differences in binding properties between antibodies expressed in bacteria and eukaryotic cells

Images